Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept
Status:
Completed
Trial end date:
2020-03-26
Target enrollment:
Participant gender:
Summary
The main objective is to evaluate the efficacy and safety of treatment with 2 doses (80 and
160 mg) of Revacept versus placebo in patients with stable coronary artery disease undergoing
PCI.
Phase:
Phase 2
Details
Lead Sponsor:
Deutsches Herzzentrum Muenchen
Collaborators:
AdvanceCor GmbH Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) German Federal Ministry of Education and Research Technische Universität München